Opto Circuits (India) Ltd’s wholly-owned subsidiary Eurocor GmbH has received CE (Communité European) Mark approval for marketing and sale of its novel Drug Eluting Stent-Taxcor Plus in world markets (sans US and Japan). Taxcor Plus is on a Cobalt Chromium platform with Stent struts of 0.0025”, which is one of the thinnest struts available in the industry. The stent is coated with Paclitaxel (1µg/mm2).

Explaining the distinctive technology of this system, Vinod Ramnani, chairman & managing director, OCI, said, “Taxcor Plus provides unique therapeutic benefits to patients requiring Drug Eluting Stents for Coronary Angioplasty. The thinnest stent struts (low profile) result in superior deliverability to culprit lesions as against the other products available in the market. Taxcor Plus is backed by years of research and has shown excellent clinical results as seen with DIOR (Eurocor’s Drug Eluting Balloon).”

Most Drug Eluting Stents (DES) available in the market have a polymer coating to keep the drug intact on the stent struts. However, in a certain group of patients, polymer coatings on DES result in an inflammatory response and a delay in SAT (sub-acute Thrombosis). Taxcor Plus doesn’t use a polymer.